Improved incidence of end-stage renal disease of type 1 diabetes in Japan, from a hospital-based survey

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Otani, Toshika ^a,b   Yokoyama, Hiroki ^c   Ohashi, Yasuo ^d   Uchigata, Yasuko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Jiyugaoka Medical Clinic   (Japan)

^d CHUO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RENIN ANGIOTENSIN SYSTEM INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETINOPATHY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 84992306069     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000177     Document Type: Article

References (26)

1. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22: 545-53.
2. Forsblom C, Harjutsalo V, Thorn LM, et al., FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011; 22: 537-44.
3. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia 2012; 55: 2301-6.
4. Matsushima M, Tajima N, LaPorte RE, et al. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International (DERI) U. S.-Japan Mortality Study Group. Diabetologia 1995; 38: 236-43.
5. Möllsten A, Svensson M, Waernbaum I, et al., Swedish Childhood Diabetes Study Group; Diabetes Incidence Study in Sweden; Swedish Renal Registry. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study. Diabetes 2010; 59: 1803-8.
6. Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-7.
7. Uchigata Y, Asao K, Matsushima M, et al. Impact on mortality and incidence of end-stage renal disease of education and treatment at a diabetes center among patients with type 1 diabetes: comparison of two subgroups in the Japanese DERI cohort. J Diabetes Complicat 2004; 18: 155-9.
8. Nishimura R, Dorman JS, Bosnyak Z, et al., Diabetes Epidemiology Research International Mortality Study; Allegheny County Registry. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003; 42: 117-24.
9. Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463-9.
10. Lecaire TJ, Klein BE, Howard KP, et al. Risk for end-stage renal disease over 25 years in the population-based WESDR cohort. Diabetes Care 2014; 37: 381-8.
11. Lin WH, Li CY, Wang WM, et al. Incidence of end stage renal disease among type 1 diabetes: a nationwide cohort study in Taiwan. Medicine (Baltimore) 2014; 93: e274.
12. Nathan DM, Zinman B, Cleary PA, et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-16.
13. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000; 58: 302-11.
14. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18.
15. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48: 1439-44.
16. Nordwall M, Abrahamsson M, Dhir M, et al. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 2015; 38: 308-15.
17. Yokoyama H, Tomonaga O, Hirayama M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-11.
18. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920-7.
19. Skupien J, Warram JH, Smiles A, et al. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol 2014; 25: 2916-25.
20. Andrésdóttir G, Jensen ML, Carstensen B, et al. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int 2015; 87: 417-26.
21. de Boer IH, Sun W, Cleary PA, et al., DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-76.
22. Hovind P, Rossing P, Tarnow L, et al. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001; 24: 1972-7.
23. Rossing K, Christensen PK, Hovind P, et al. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005; 48: 2241-7.
24. de Galan BE, Perkovic V, Ninomiya T, et al., ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-92.
25. Ismail-Beigi F, Craven TE, O'Connor PJ, et al., ACCORD Study Group. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 2012; 81: 586-94.
26. Yokoyama H, Araki S, Honjo J, et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 2013; 36: 3227-33.